Erythropoiesis-stimulating agents in patients with hematologic malignancies in Newfoundland and Labrador

• Main Author: Sheppard, Dawn C. (Dawn Catherine)
• Format: Thesis
• Language: English
• Published: Memorial University of Newfoundland 2008
• Subjects: Newfoundland
• Online Access: https://research.library.mun.ca/9133/; https://research.library.mun.ca/9133/1/Sheppard_DawnC.pdf

Anemia is common in cancer patients. Erythropoiesis-Stimulating agents (ESAs) improve hemoglobin concentrations, decrease transfusion requirements and may improve quality of life. The American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) published guidelines for their use in 2002. The first objective was to estimate the number of patients with hematologic malignancies in Newfoundland and Labrador, who meet these criteria, that actually receive an ESA. The second objective was to determine whether there are demographic factors associated with receiving an ESA. The third objective was to review the literature around ESA use, tumor progression and survival. A review of the medical charts of 110 patients meeting the ASH/ASCO guidelines was undertaken. Patients had an average hemoglobin of 89.1g/L, spent 75% of the time with a hemoglobin under 100 g/L and received an average of one transfusion every three weeks. More patients living in urban areas received an ESA than in rural areas. ESAs are important in supportive cancer care and measures should be taken to meet national standards.